- Home
- SNDX vs PFLT Comparison
SNDX vs PFLT Comparison
Compare SNDX & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- PFLT
- Stock Information
- Founded
- SNDX 2005
- PFLT 2010
- Country
- SNDX United States
- PFLT United States
- Employees
- SNDX N/A
- PFLT N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- PFLT Finance: Consumer Services
- Sector
- SNDX Health Care
- PFLT Finance
- Exchange
- SNDX Nasdaq
- PFLT Nasdaq
- Market Cap
- SNDX 1.1B
- PFLT 1.1B
- IPO Year
- SNDX 2016
- PFLT N/A
- Fundamental
- Price
- SNDX $9.92
- PFLT $10.47
- Analyst Decision
- SNDX Strong Buy
- PFLT Buy
- Analyst Count
- SNDX 11
- PFLT 5
- Target Price
- SNDX $34.00
- PFLT $11.05
- AVG Volume (30 Days)
- SNDX 1.7M
- PFLT 636.8K
- Earning Date
- SNDX 08-04-2025
- PFLT 08-11-2025
- Dividend Yield
- SNDX N/A
- PFLT 11.75%
- EPS Growth
- SNDX N/A
- PFLT N/A
- EPS
- SNDX N/A
- PFLT 0.86
- Revenue
- SNDX $43,722,000.00
- PFLT $232,975,000.00
- Revenue This Year
- SNDX $431.08
- PFLT $45.12
- Revenue Next Year
- SNDX $105.38
- PFLT $9.18
- P/E Ratio
- SNDX N/A
- PFLT $12.15
- Revenue Growth
- SNDX N/A
- PFLT 49.56
- 52 Week Low
- SNDX $8.58
- PFLT $8.82
- 52 Week High
- SNDX $23.37
- PFLT $11.90
- Technical
- Relative Strength Index (RSI)
- SNDX 51.66
- PFLT 45.44
- Support Level
- SNDX $9.42
- PFLT $10.40
- Resistance Level
- SNDX $10.75
- PFLT $10.66
- Average True Range (ATR)
- SNDX 0.58
- PFLT 0.14
- MACD
- SNDX 0.08
- PFLT -0.04
- Stochastic Oscillator
- SNDX 51.74
- PFLT 13.54
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.